Artículos con órdenes de acceso público - Lars WallentinMás información
TotalNIHBHFMRCNIHRSwedish Research CouncilWellcomeAHADFGEuropean CommissionDHFCIHRBMBFINSERMESRCVersus Arthritis, UKLeducq Foundation, USAHSFFORTECancer Research UKEPSRCCSOHealth Data Research, UKRoyal Society UKNHMRCNWOKnut and Alice Wallenberg FoundationUK Research & InnovationNSERCAcademy of FinlandZonMwRCNGobierno de EspañaPCORIGovernment of ItalySNSFVAHelmholtzBBSRCARRSDoris Duke Charitable FoundationGatesFRQSNSFCDCTIMarianne and Marcus Wallenberg FoundationMESTD
No disponibles en ningún lugar: 29
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib …
H White, C Held, R Stewart, D Watson, R Harrington, A Budaj, PG Steg, ...
American Heart Journal 160 (4), 655-661. e2, 2010
Órdenes: US National Institutes of Health
Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a …
P Damman, T Clayton, L Wallentin, B Lagerqvist, KAA Fox, A Hirsch, ...
Heart 98 (3), 207-213, 2012
Órdenes: British Heart Foundation
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
KP Alexander, MA Brouwer, H Mulder, D Vinereanu, RD Lopes, M Proietti, ...
American Heart Journal 208, 123-131, 2019
Órdenes: US National Institutes of Health
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
G Ducrocq, PJ Schulte, A Budaj, JH Cornel, C Held, A Himmelmann, ...
American heart journal 186, 91-99, 2017
Órdenes: National Institute of Health and Medical Research, France
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA• CER) trial: study design and rationale
TRA The, CER Executive, S Committees
American Heart Journal 158 (3), 327-334. e4, 2009
Órdenes: US National Institutes of Health
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome
CN Hess, RM Clare, ML Neely, P Tricoci, KW Mahaffey, SK James, ...
American heart journal 187, 194-203, 2017
Órdenes: US National Institutes of Health, American Heart Association
Biomarkers and coronary lesions predict outcomes after revascularization in non–ST-elevation acute coronary syndrome
D Lindholm, SK James, M Bertilsson, RC Becker, CP Cannon, ...
Clinical chemistry 63 (2), 573-584, 2017
Órdenes: US National Institutes of Health
Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials)
P Damman, L Holmvang, JGP Tijssen, B Lagerqvist, TC Clayton, ...
The American journal of cardiology 109 (1), 6-12, 2012
Órdenes: British Heart Foundation
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the …
YJ Shimada, S Bansilal, SD Wiviott, RC Becker, RA Harrington, ...
American heart journal 177, 1-8, 2016
Órdenes: US National Institutes of Health, American Heart Association
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease
R De Caterina, S Husted, L Wallentin, F Andreotti, H Arnesen, ...
Thrombosis and Haemostasis 115 (04), 685-711, 2016
Órdenes: UK Medical Research Council
The direct thrombin inhibitors dabigatran and lepirudin inhibit GPIbα-mediated platelet aggregation
K Trabold, S Makhoul, S Gambaryan, J van Ryn, U Walter, K Jurk
Thrombosis and haemostasis 119 (06), 916-929, 2019
Órdenes: Federal Ministry of Education and Research, Germany
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic …
DA Garcia, DA Fisher, H Mulder, L Wruck, R De Caterina, S Halvorsen, ...
American Heart Journal 221, 1-8, 2020
Órdenes: US National Institutes of Health
Individual patient data from the pivotal randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (COMBINE AF): design …
AP Carnicelli, H Hong, RP Giugliano, SJ Connolly, J Eikelboom, MR Patel, ...
American Heart Journal 233, 48-58, 2021
Órdenes: US National Institutes of Health, American Heart Association
Imbalance between fibrin clot formation and fibrinolysis predicts cardiovascular events in patients with stable coronary artery disease
S Neergaard-Petersen, SB Larsen, EL Grove, SD Kristensen, RA Ajjan, ...
Thrombosis and haemostasis 120 (01), 075-082, 2020
Órdenes: Danish Council for Technology and Innovation
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial
JB Washam, SH Hohnloser, RD Lopes, DM Wojdyla, D Vinereanu, ...
Journal of Thrombosis and Thrombolysis 47, 345-352, 2019
Órdenes: US National Institutes of Health
Impact of an invasive strategy on 5 years outcome in men and women with non–ST-segment elevation acute coronary syndromes
J Alfredsson, T Clayton, P Damman, KAA Fox, M Fredriksson, ...
American heart journal 168 (4), 522-529, 2014
Órdenes: British Heart Foundation
Usefulness and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial)
M Valgimigli, P Tricoci, Z Huang, PE Aylward, PW Armstrong, ...
The American Journal of Cardiology 114 (5), 665-673, 2014
Órdenes: US National Institutes of Health
Cardiovascular outcomes according to polypharmacy and drug adherence in patients with atrial fibrillation on long-term anticoagulation (from the RE-LY trial)
D Millenaar, H Schumacher, M Brueckmann, JW Eikelboom, M Ezekowitz, ...
The American journal of cardiology 149, 27-35, 2021
Órdenes: German Research Foundation
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial
D Kopin, WS Jones, MW Sherwood, DM Wojdyla, L Wallentin, BS Lewis, ...
American Heart Journal 197, 133-141, 2018
Órdenes: American Heart Association, Patient-Centered Outcomes Research Institute
Glycoprotein IIb/IIIa receptor inhibitors in combination with vorapaxar, a platelet thrombin receptor antagonist, among patients with non–ST-segment elevation acute coronary …
JH Cornel, P Tricoci, Y Lokhnygina, DJ Moliterno, L Wallentin, ...
The American Journal of Cardiology 115 (10), 1325-1332, 2015
Órdenes: US National Institutes of Health
La información de publicación y financiación se determina de forma automática mediante un programa informático